{
    "clinical_study": {
        "@rank": "129254", 
        "brief_summary": {
            "textblock": "This is an observational study to assess the experience of current depot medroxyprogesterone\n      acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject\n      and offer recommendations for the introduction of this method."
        }, 
        "brief_title": "Acceptability of Depo-subQ in Uniject", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Contraception", 
        "detailed_description": {
            "textblock": "This is an observational study to assess the experience of current depot medroxyprogesterone\n      acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject\n      and offer recommendations for the introduction of this method.\n\n      A total of 560 participants will be enrolled in the study in the following groups:\n\n      360 participants (120 in Uganda and 240 in Senegal) who are current DMPA IM clients who seek\n      re-injection of DMPA from either community health workers (CHWs) or clinic-based providers;\n      and are 18-40 years of age; received their most recent DMPA injection no more than 13 weeks\n      prior to enrollment in the study [16].\n\n      Up to 100 participants (50 in Uganda and 50 in Senegal) current DMPA IM clients who meet the\n      inclusion/exclusion criteria but do not want to receive the injection with Depo-subQ in\n      Uniject and are willing to complete a short questionnaire\n\n      80 CHWs (40 in Uganda and 40 in Senegal) and 20 clinic-based providers (from Senegal only)\n      who are trained to give Depo-subQ in Uniject as part of this study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-40\n\n          -  In general good health (the participant verbally reports she feels well)\n\n          -  Using DMPA continuously for at least six months prior to enrollment in the study\n             (i.e., had at least two previous injections)\n\n          -  Received their most recent DMPA injection no more than 13 weeks prior to enrollment\n             in the study at the study clinic or from a family planning provider involved in the\n             study (Senegal only)\n\n          -  Received their most recent DMPA injection no more than 13 weeks prior to enrollment\n             in the study from a family planning provider involved in the study (Uganda only)\n\n          -  Desires to be re-injected with DMPA\n\n          -  Willing to sign an informed consent document\n\n          -  Willing to provide contact information and be interviewed three months after\n             enrollment."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "A total of 560 participants will be enrolled in the study in the following groups:\n\n          -  360 participants (120 in Uganda and 240 in Senegal) who are current DMPA IM clients\n             who seek re-injection of DMPA from either CHWs or clinic-based providers; and are\n             18-40 years of age; received their most recent DMPA injection no more than 13 weeks\n             prior to enrollment in the study [16].\n\n          -  Up to 100 participants (50 in Uganda and 50 in Senegal) current DMPA IM clients who\n             meet the inclusion/exclusion criteria but do not want to receive the injection with\n             Depo-subQ in Uniject and are willing to complete a short questionnaire\n\n          -  80 CHWs (40 in Uganda and 40 in Senegal) and 20 clinic-based providers (from Senegal\n             only) who are trained to give Depo-subQ in Uniject as part of this study"
            }
        }, 
        "enrollment": {
            "#text": "476", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667276", 
            "org_study_id": "10196"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "AE     adverse event", 
            "AIDS     acquired immunodeficiency syndrome", 
            "ALT (SGPT)    alanine aminotransferase", 
            "ART    antiretroviral therapy", 
            "AST (SGOT)    aspartate aminotransferase", 
            "DCF    data collection forms", 
            "DMC     Data Monitoring Committee", 
            "FDA     (U.S.) Food and Drug Administration", 
            "GCP     Good Clinical Practice guidelines", 
            "HB sAg   Hepatitis B surface antigen", 
            "ICH     International Conference of Harmonisation", 
            "IND    Investigational New Drug Application", 
            "IRB     Institutional Review Board", 
            "IU    international units", 
            "mg     milligram(s)", 
            "mm3     cubic millimeter(s)", 
            "PCR     polymerase chain reaction", 
            "SAE     serious adverse event", 
            "\u00b5g     microgram", 
            "ULN     upper limit of the normal range", 
            "WB    Western Blot"
        ], 
        "lastchanged_date": "July 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "All Cities Where There Is A Clinic", 
                        "country": "Senegal"
                    }, 
                    "name": "Ministry of Health Clinics"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "All Cities Where There Is A Clinic", 
                        "country": "Uganda"
                    }, 
                    "name": "Ministry of Health Clinics, Uganda"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Senegal", 
                "Uganda"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Acceptability of Depo-subQ in Uniject", 
        "overall_official": [
            {
                "affiliation": "FHI 360", 
                "last_name": "Holly Burke, PhD, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ministry of Health, Uganda", 
                "last_name": "Anthony Mbonye, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Division de la Sante de la Reproduction", 
                "last_name": "Bpcar M Daff, MD, PhD, MSc", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "percent of participants who declare they would select Depo-subQ in Uniject for their next injection if this drug product was available at three months with a 95% confidence interval per country", 
                "measure": "Measure the acceptability of Depo-subQ in Uniject among DMPA IM family planning clients;", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "key themes will be identified from interview transcripts to summarize family planning providers' (clinic-based and CHWs) acceptability of Depo-subQ in Uniject and preference for administering Depo-subQ in Uniject relative to the typical DMPA intramuscular injection by county", 
                "measure": "2) Measure the acceptability of Depo-subQ in Uniject among family planning providers (both clinic-based and CHWs);", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "descriptive analyses (e.g., frequencies and means) of responses for quantitative questions and summaries providers' qualitative responses to open-ended questions from the post-training evaluation for each country", 
                "measure": "Assess family planning providers' (clinic-based and CHWs) training materials.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667276"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "frequencies and summary statistics of acceptability data among family planning clients by asking participants to compare their experiences receiving Depo-subQ in Uniject to their experiences receiving the typical DMPA intramuscular injection by country", 
                "measure": "1) To qualitatively compare acceptability of Depo-subQ in Uniject among the two types of family planning providers\u2014clinic-based and CHWs (Senegal only)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "frequencies of reported adverse events by country", 
                "measure": "2) To assess the safety of participants who receive Depo-subQ in Uniject during the study", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "FHI 360", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "United States Agency for International Development (USAID)", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "PATH", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "FHI 360", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}